<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163146">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974363</url>
  </required_header>
  <id_info>
    <org_study_id>112148</org_study_id>
    <nct_id>NCT00974363</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612</brief_title>
  <official_title>Persistence of Antibodies After Vaccination With GSK Biologicals' Meningococcal Vaccine GSK134612 in Adolescents and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Subjects were previously vaccinated at 11 to 17 years of age. This extension phase starts 24
      months after vaccination and the subjects who were vaccinated in the primary study will be
      enrolled in this extension phase. No new subjects will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were previously vaccinated at 11 to 17 months of age with GSK Biologicals'
      meningococcal vaccine 134612 or with Mencevaxâ„¢. This extension phase starts 24 months after
      vaccination and the subjects who were vaccinated in the primary study will be enrolled in
      this extension phase. No new studies will be enrolled. The subjects will have 4 blood
      samples taken: at 24, 36, 48 and 60 months after vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Persistence of immunogenicity with respect to components of the investigational vaccine</measure>
    <time_frame>24, 36, 48 and 60 months post primary dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of immunogenicity with respect to components of the investigational vaccine (on secondary readouts)</measure>
    <time_frame>24, 36, 48 and 60 months post primary dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">697</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received GSK Biologicals' meningococcal vaccine 134612 in the primary vaccination study 109069.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who received MencevaxTM ACWY in the primary vaccination study 109069.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Sampling</intervention_name>
    <description>A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parent(s)/guardian(s)
             can and will comply with the requirements of the protocol should be enrolled in the
             study.

          -  A male or female having been vaccinated with a meningococcal vaccine in the primary
             study 109069.

          -  Written informed consent obtained from parent(s)/guardian(s) of the subject and
             written informed assent obtained from the subject if the subject is less than 18
             years of age, or written informed consent obtained from the subject if the subject
             has achieved the 18th birthday.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding the subject's first visit.

          -  History of meningococcal disease; such cases will be documented.

          -  Administration of a meningococcal polysaccharide or a meningococcal polysaccharide
             conjugate vaccine since previous vaccination in study 109069.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the subject's first visit.

          -  Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy

          -  Subjects who withdrew consent to be contacted for follow-up studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goa</city>
        <zip>403202</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indore</city>
        <zip>452001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 21, 2016</lastchanged_date>
  <firstreceived_date>September 7, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meningococcal vaccine GSK 134612</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
